TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05933005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-kit/EF1
Description: D-kit/EF1 delivers interventions through online platforms and can be downloaded to smart devices through the iOS App store or Google Play Store. Games are specifically designed to assist children with delayed cognitive development in the acquisition of foundational cognitive skills.~The core technology of the D-kit/EF1 is the 'reinforcement technique', a technology used in traditional behavioral therapy. Specifically, D-kit incorporates the Discrete Trial Training (DTT) approach into its instructional content to facilitate the acquisition of basic cognitive skills.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group program
Description: The sham program was designed to provide a similar experience as the experimental group by replacing the content within the same app. The control group uses the same mobile tablet device and accesses the app with the provided control group account. When accessing the app with the control group account, instead of the Adaptive Learning Lesson reflecting the principles of D-kit, educational animations created for educational purposes are provided.
Study: NCT05198050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole tablets
Description: Letrozole is a third-generation non-steroidal aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole tablets
Description: Letrozole is a third-generation non-steroidal aromatase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Tabets
Description: a synthetic prostaglandin medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Tabets
Description: a synthetic prostaglandin medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Tabets
Description: a synthetic prostaglandin medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tables with a similar appearance to letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tables with a similar appearance to letrozole
Study: NCT05425147

Intervention type: OTHER
Intervention: Perioperative autonomic function assessment
Description: Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.

Intervention type: OTHER
Intervention: Perioperative autonomic function assessment
Description: Patients will have BRS and HRV measurements taken for approximately 20 minutes, one day before surgery and on the day of surgery. We use LiDCO rapid to conduct non-invasive pulse and beat-to-beat blood pressure monitoring.
Study: NCT06324149

Intervention type: DIAGNOSTIC_TEST
Intervention: completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis
Description: The sub-investigator performs a multidimentional geriatric evaluation

Intervention type: DIAGNOSTIC_TEST
Intervention: completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis
Description: The sub-investigator performs a multidimentional geriatric evaluation
Study: NCT05655832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivalink wearable device
Description: a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivalink wearable device
Description: a CE marked device modified to add a temperature measurement algorithm in addition to ECG and respiratory rate measurements
Study: NCT05400382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Meditation training to help reduce stress and reactivity to pain and other stressors.
Study: NCT06162923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site video group
Description: Each participant will receive standard oral hygiene reinforcement verbally, followed by watching a pre-recorded oral hygiene instruction video on a tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote video group
Description: After receiving normal oral hygiene reinforcement verbally, each participant will be sent a video link Whatapps instant message, which they are required to watch at home
Study: NCT05277753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CAR-T/CTL and DCvac
Description: Antigen-specific T cells CAR-T/CTL and DCvac cells to treat T-ALL
Study: NCT05064319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive gabapentin 2-3 times a day for a total of 17 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After group assignment but before taking any study medication, and again 17 days later, participants will have a Magnetic Resonance Imaging (MRI) exam after completing various assessments (clinical interview, questionnaires, etc.). Group A will receive placebo 2-3 times a day for a total of 17 days.
Study: NCT05252130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoaScope
Description: Smart digital stethoscope
Study: NCT04988061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counselling
Description: Educating and Counselling with personal communication for 10-15 minutes and written information about the importance of early identification and intervention for hearing loss are provided by a physician. Also, the information about hearing screening results and an appointment date are provided by a physician.
Study: NCT05885139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exopulse Mollii Suit
Description: Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Exopulse Mollii Suit
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study: NCT03974256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the use of the automaton
Description: 2 days training on automaton use
Study: NCT05133609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (AZD1222)
Description: ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (AZD1222)
Description: ChAdOx1 nCoV-19 vaccine (AZD1222) in a standard 3-dose schedule with an interval of 12 weeks (first-second dose) and 24 weeks (second-third dose).
Study: NCT05223582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Patients would be treated with 1000mg abiraterone qd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Patients would be treated with 150mg fluzoparib bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients would be treated with 5mg prednisone bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Patients would get medical castration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Patients would get radical prostatectomy after the neoadjuvant treatment.
Study: NCT06485258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Description: CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)
Description: CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL sterile saline administered via IM injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL sterile saline administered via IM injection
Study: NCT05701371

Intervention type: OTHER
Intervention: Biological samples collection
Description: blood drawing + feces collection in a dedicated device
Study: NCT05597345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
Study: NCT04842045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin and Midazolam
Description: The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight.
Study: NCT05309421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVX-01
Description: Investigational drug given in combination with standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML
Description: Standard of care
Study: NCT05127577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage will be applied to patients at least 30 minutes after morning and evening meals (8:30 in the morning, 20:30 in the evening) for 15 minutes each, similar to the literature \[33,34,38\]. Data of the patients will be collected again 15 minutes after the application of abdominal massage (09:00-09:15 in the morning, 21:00-21:15 in the evening). Abdominal massage will start in the evening of the day the patient is transferred to the clinic (20:30), and will be terminated when the patient defecates. In order to stimulate bowel movements, four basic movements will be used in the abdominal massage to be applied clockwise: superficial effusion, deep effusion, petrissage, and vibration.
Study: NCT05803746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT05389943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of vitamin D3
Description: the effect of oral supplement in postmenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50000 UNT Oral Capsule
Description: In postmenopausal women with BMD less than 32 ng/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk, Dietary and life style modifications.
Description: Postmenopausal women with BMD greater than 32 ng/ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk, Dietary and life style modifications.
Description: Postmenopausal women with BMD greater than 32 ng/ml
Study: NCT05065645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin Converting Enzyme 2
Description: SAD: single dose; MAD: dosage 2x daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: SAD: single dose; MAD: dosage 2x daily for 7 days
Study: NCT04963192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected actimeter to measure physical activity in OSA patients
Description: Connected actimeter worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for OSA patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure physical activity in COPD patients only
Description: Connected BORA Band worn for one week before initiation of treatment, at M3 and at M6, to measure average daily steps for COPD patients only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPAQ to evaluated physical activity
Description: Physical activity evaluated by IPAQ (International Physical Activity Questionnaire) at the inclusion, M3 and M6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected scale to measure weight
Description: Weight measured by a connected scale, before CPAP or NIV treatment, at M3 and M6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected tensiometer to measure arterial pressure
Description: Arterial pressure measured by a connected tensiometer, before CPAP or NIV treatment, at M3 and M6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure oxygen saturation in COPD patients only
Description: Daily oxygen saturation measured by the connected BORA Band for COPD patients only during 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure heart rate in COPD patients only
Description: Daily heart rate measured by the connected BORA Band for COPD patients only during 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected BORA Band to measure respiratory rate in COPD patients only
Description: Daily respiratory rate measured by the connected BORA Band for COPD patients only during 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXASCORE to evaluated COPD severity
Description: COPD severity evaluated by the EXASCORE questionnaire at inclusion, M3 and M6 for COPD patients only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epworth scale to evaluate sleepiness
Description: Sleepiness evaluated by the Epworth scale at baseline, M3 and M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pichot scale to evaluate fatigue
Description: Fatigue evaluated by the Pichot scale at inclusion, M3 and M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability questionnaire
Description: Subjective assessment of each device by means of usability questionnaire at M6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: Quality of life evaluated by the SF36 questionnaire at inclusion and M6
Study: NCT05554653

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine enriched amino acids
Description: Leucine enriched essential amino acids (4g total, of which 1.6g are leucine). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Placebo
Description: iso-caloric placebo (4g maltodextrin). 20g carbohydrate, 2g of protein free drink powder, and 5g of Splenda.
Study: NCT05621265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Text messaging
Description: daily text message
Study: NCT06304701

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive and writing tests
Description: * Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive and writing tests
Description: * Wechsler Adult Intelligence Scale - fourth edition (Similarities and Vocabulary subtests)~* MASC (Movie for assessment of social cognition)~* Rey figure~* BHK (Quick Writing Assessment Scale)~* Descriptive text writing~* Persuasive text writing
Study: NCT00012857

Intervention type: DRUG
Group type: OTHER
Intervention: acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN
Study: NCT05331222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-1
Description: JT-1 is a physiological salt with recently detected pharmacological properties that warrant testing for its therapeutic potential in chronic rhinitis and chronic sinusitis.
Study: NCT06235398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell transplantation
Description: Upfront related donor transplantation
Study: NCT05668481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic sleep and circadian intervention (TranS-C)
Description: TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transdiagnostic sleep and circadian intervention (TranS-C)
Description: TranS-C is a psychosocial treatment that helps people who have sleep and circadian problems to improve their sleep health.
Study: NCT05894161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: The designed exercise program will be distributed on everyone. The recommendations will be to train from 30 to 45 minutes, 3 days per week for 6 weeks in addition to walking 30 minutes on the ground surface daily.~1. Diaphragmatic Breathing Exercises: Diaphragmatic breathing (DBRT) or abdominal deep breathing is an expansion of the abdominal area rather than the thoracic area when breathing.~2. Progressive Muscle Relaxation (PMR): The physical element includes the tensing and relaxing of all muscle groups over the face, arms, trunk (abdomen \& chest) and legs.~3. A combination of stretching, stabilization and strengthening exercises of the pelvic-lumbar region:~4. Walking exercise: Walking on the ground surface for 30 minutes every day.
Study: NCT05818696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling (LMC)
Description: The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling (LMC)
Description: The research interventionist uses a guiding approach to identify methods for secure firearm storage and reflects the participant's reasons for and against secure firearm storage, with a particular focus on the service member's verbalized reasons for wanting to adopt or use the identified storage methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Uncertainty - Enhanced (CUE)
Description: CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Uncertainty - Enhanced (CUE)
Description: CUE consists of a 1-hour manualized intervention that uses interactive content to enhance participant learning of critical intervention components. The session includes (1) psychoeducation regarding the role of IU in exacerbating anxiety/mood sensations, (2) practice identifying and challenging maladaptive thoughts about uncertainty and accompanying distress, and (3) behavioral activities to challenge participants' capacity to handle uncertainty.
Study: NCT06056479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external oblique intercostal block
Description: 20 ml of bupivacaine 0.25% will be administered by US into external oblique intercostal plane at the level of sixth rib space .
Study: NCT05491083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab & ADG106 (Phase Ib)
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab & ADG106 (Phase II)
Description: Drug: ADG106~Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.~Pembrolizumab~Administered as an intravenous infusion over 30 minutes
Study: NCT06196242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and CT scan
Description: An MRI scan of the head in about 30 minutes. During the scan, MRI thermometry will be performed to monitor for possible lead heating due to the interaction of the MRI radiofrequency field and the implanted devices.~An CT plain scan of the head in about 10 minutes.
Study: NCT05575271

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
Description: The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
Description: The implant surgery is performed under general anesthesia. The generator is implanted subcutaneously in the left upper chest or left axillary border. The electrode lead wire is attached to the left mid-cervical vagus nerve through a second incision in the left neck area. The lead wire is passed through a subcutaneous tunnel and attached to the pulse generator.